Tier 2 — strong

Quercetin lowers plasma uric acid in pre-hyperuricaemic males: a randomised, double-blinded, placebo-controlled, cross-over trial

Yuanlu Shi, Gary Williamson
The British journal of nutrition 2016 115(5):800

Bibliography

PubMed
PMID 26785820
DOI
10.1017/S0007114515005310
Funding
Funding was not specified in the indexed record or the disclosure metadata available for this entry.
Competing interests
A competing-interest declaration was not available in the indexed record or the disclosure metadata used for this entry.

Study snapshot

DesignRandomized double-blind placebo-controlled crossover trial
ModelHuman intervention research
Sample22 healthy men with high-normal uric acid
InterventionQuercetin 500 mg/day versus placebo
Duration4-week treatment periods with 4-week washout
EndpointsBlood pressure; Glucose and insulin measures; Exposure and pharmacokinetics; Uric acid

What the study showed, in plain terms

Published in 2016, this source examined uric acid and gout. Design: Randomized double-blind placebo-controlled crossover trial. Sample/model: 22 healthy men with high-normal uric acid. The exposure or intervention was Quercetin 500 mg/day versus placebo. Follow-up or treatment period: 4-week treatment periods with 4-week washout.

Uric acid decreased by about 26.5 micromol/L, while fasting glucose, pressure and urinary uric-acid excretion did not change.

Short study in men without established gout. Prevention of gout attacks, kidney stones or long-term complications was not tested.

Continue with Quercetin Data Center

For topic-level interpretation, read Quercetin for Uric Acid and Gout: What the Trial Shows. This is a related guide; the citation panel separately identifies articles that directly cite this paper.

Key findings

  • Uric acid decreased by about 26.5 micromol/L, while fasting glucose, pressure and urinary uric-acid excretion did not change.
  • The recorded outcome domains were Blood pressure; Glucose and insulin measures; Exposure and pharmacokinetics; Uric acid.
  • The result applies to the tested exposure: Quercetin 500 mg/day versus placebo; 4-week treatment periods with 4-week washout.

What this study can and cannot tell us

  • Short study in men without established gout. Prevention of gout attacks, kidney stones or long-term complications was not tested.
  • An individual controlled trial must be interpreted alongside its comparator, sample size, endpoint selection and independent replication. It does not validate a different commercial formulation or a general longevity claim.
  • Source basis: Source check: PubMed abstract and indexed metadata; full methods were not independently confirmed for this entry. Missing method details, funding information or participant denominators are not inferred.

Related papers in the corpus

Tier 2
Effect of quercetin on the echocardiographic parameters of left ventricular diastolic function in patients with gout and essential hypertension
Vitalii E Kondratiuk et al. · Wiadomosci lekarskie (Warsaw, Poland : 1960) · 2018

Citation network

Articles citing this research paper

4 articles

Biohack Blueprint analyses that reference this study in their evidence base.

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology